Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
FLNT Fluent Inc
CCXI ChemoCentryx Inc
NVTA Invitae Corp
CLNE Clean Energy Fuels Corp
IMBBY Imperial Brands PLC
T AT&T Inc
JNJ Johnson & Johnson
GMS GMS Inc
TMUS T-Mobile US Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Closing Price
$61.60
Day's Change
0.51 (0.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
61.71
Day's Low
60.81
Volume
(Below Average)
Volume:
5,857,705

10-day average volume:
6,873,514
5,857,705

Latest Earnings (Year ending 12/2021)

$7.28
Consensus estimate
$8.16

Latest Earnings Estimate Range

Highest
estimate
$8.74
Mean
estimate
$8.16
Lowest
estimate
$7.54

Annual Consensus Estimates and Ranges

GILD's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.